Yb dhr lb dhvreb fnore rf fv yn ureznan l ry crfpnqb fr una pbasrfnqb fh nzbe l chrqra ivive ra cnm, ragvraqb dhr fv cbe yn fbzoen dhr fr ir ny svany.
September 20, 2026 at 7:35 PM
Yb dhr lb dhvreb fnore rf fv yn ureznan l ry crfpnqb fr una pbasrfnqb fh nzbe l chrqra ivive ra cnm, ragvraqb dhr fv cbe yn fbzoen dhr fr ir ny svany.
Day 2, MILK PBPK PhD scholar Joshua Kiptoo introduced participants to In Vitro–In Vivo Extrapolation (IVIVE), demonstrating how in vitro data & mechanistic models predict drug clearance & exposure to support smarter drug development. #IVIVE #Pharmacometrics #DrugDevelopment @seniorcymo.bsky.social
July 31, 2026 at 12:24 PM
Day 2, MILK PBPK PhD scholar Joshua Kiptoo introduced participants to In Vitro–In Vivo Extrapolation (IVIVE), demonstrating how in vitro data & mechanistic models predict drug clearance & exposure to support smarter drug development. #IVIVE #Pharmacometrics #DrugDevelopment @seniorcymo.bsky.social
During his presentation, Joshua demonstrated how in vitro data and mechanistic models predict drug clearance and exposure to support smarter drug development. #IVIVE #PBPK #Pharmacometrics #DrugDevelopment
July 31, 2026 at 7:39 PM
During his presentation, Joshua demonstrated how in vitro data and mechanistic models predict drug clearance and exposure to support smarter drug development. #IVIVE #PBPK #Pharmacometrics #DrugDevelopment
Ohrab, ur ivfgb dhr unl qbf cryíphynf záf, creb zv ireqnqren certhagn ren pózb von n fnyine rfgb n yn uhznavqnq ernyzragr. Fv rf dhr cnfna n ivive gbqbf ra ry cynab baíevpb nhadhr yn cnyzra vey b dhé. Creb fv yb rkcyvpna ra ynf cryvf cersvreb ireynf cevzreb, tenpvnf
May 2, 2025 at 8:16 AM
Ohrab, ur ivfgb dhr unl qbf cryíphynf záf, creb zv ireqnqren certhagn ren pózb von n fnyine rfgb n yn uhznavqnq ernyzragr. Fv rf dhr cnfna n ivive gbqbf ra ry cynab baíevpb nhadhr yn cnyzra vey b dhé. Creb fv yb rkcyvpna ra ynf cryvf cersvreb ireynf cevzreb, tenpvnf
Bgen pbfn dhr cbqevn vagrecergne ry raqvat rf pbzb dhr Ynen rf yvoer, dhvrer ivive ra ry zhaqb uhznab l grare ha uhrpb ra ry dhr cbqre cregrarpre l fre yvoer qry fvfgrzn.
September 20, 2026 at 7:07 PM
Bgen pbfn dhr cbqevn vagrecergne ry raqvat rf pbzb dhr Ynen rf yvoer, dhvrer ivive ra ry zhaqb uhznab l grare ha uhrpb ra ry dhr cbqre cregrarpre l fre yvoer qry fvfgrzn.
phnaqb frn Znev obkre cebsrfvbany, nqrznf Ynen unoynon ra frevb qr ivive whagnf. Ra ry svany ab shr ha nqvbf cnen fvrzcer. Qvwb fvzcyrzragr dhr ab ibyiren vazrqvngnzragr, dhvreb crafne dhr Ynen fvzcyrzragr dhvrer hfne ybf cebcvbf cvrf dhr un bogravqb cnen frthve nqrynagr qrfphoevraqb znf qry zhaqb
September 20, 2026 at 5:08 PM
phnaqb frn Znev obkre cebsrfvbany, nqrznf Ynen unoynon ra frevb qr ivive whagnf. Ra ry svany ab shr ha nqvbf cnen fvrzcer. Qvwb fvzcyrzragr dhr ab ibyiren vazrqvngnzragr, dhvreb crafne dhr Ynen fvzcyrzragr dhvrer hfne ybf cebcvbf cvrf dhr un bogravqb cnen frthve nqrynagr qrfphoevraqb znf qry zhaqb
Spoilers xD rot13
Zr un urpub tenpvn dhr cbe pnfv fre zngnqn cbe ha bfb yn cebgn ab unln fnygnqb creb grare ha frkb fúcre qrprcpvbanagr pba ha senapéf yr unln dhvgnqb ynf tnanf qr ivive
Zr un urpub tenpvn dhr cbe pnfv fre zngnqn cbe ha bfb yn cebgn ab unln fnygnqb creb grare ha frkb fúcre qrprcpvbanagr pba ha senapéf yr unln dhvgnqb ynf tnanf qr ivive
August 23, 2026 at 10:49 AM
Spoilers xD rot13
Zr un urpub tenpvn dhr cbe pnfv fre zngnqn cbe ha bfb yn cebgn ab unln fnygnqb creb grare ha frkb fúcre qrprcpvbanagr pba ha senapéf yr unln dhvgnqb ynf tnanf qr ivive
Zr un urpub tenpvn dhr cbe pnfv fre zngnqn cbe ha bfb yn cebgn ab unln fnygnqb creb grare ha frkb fúcre qrprcpvbanagr pba ha senapéf yr unln dhvgnqb ynf tnanf qr ivive
🧩#ZeroPMPieces #22 Abishek Laxmanan Ravi Shankar from Fraunhofer ITEM presents physiologically based kinetic (#PBK) Modelling using in vitro to in vivo extrapolation (#IVIVE) analyses to predict the toxicokinetic profiles of triazoles (and triazines and #PFAS)
Video: youtu.be/PzaRPNrhw0Y
Video: youtu.be/PzaRPNrhw0Y
ZeroPM pieces #22: PBK Modelling using IVIVE to predict the toxicokinetic profiles of triazoles
YouTube video by ZeroPM - H2020
youtu.be
December 9, 2024 at 12:45 AM
🧩#ZeroPMPieces #22 Abishek Laxmanan Ravi Shankar from Fraunhofer ITEM presents physiologically based kinetic (#PBK) Modelling using in vitro to in vivo extrapolation (#IVIVE) analyses to predict the toxicokinetic profiles of triazoles (and triazines and #PFAS)
Video: youtu.be/PzaRPNrhw0Y
Video: youtu.be/PzaRPNrhw0Y
October 2025 ToxSci #ToxSpotlight Article—AIVIVE: A Novel AI Framework for Enhanced In Vitro to In Vivo Extrapolation (IVIVE) of Toxicogenomics Data #OpenAccess academic.oup.com/toxsci/artic...
October 6, 2025 at 5:37 PM
October 2025 ToxSci #ToxSpotlight Article—AIVIVE: A Novel AI Framework for Enhanced In Vitro to In Vivo Extrapolation (IVIVE) of Toxicogenomics Data #OpenAccess academic.oup.com/toxsci/artic...
Publication alert 🚨: pubmed.ncbi.nlm.nih.gov/39884812/
#QconCAT-based targeted #proteomics to quantify the abundance of 6 transporters and 1 plasma protein marker in 5 placenta samples and associated cell lines and use of the data in a #PBPK model for IVIVE-based prediction of fetal drug exposure.
#QconCAT-based targeted #proteomics to quantify the abundance of 6 transporters and 1 plasma protein marker in 5 placenta samples and associated cell lines and use of the data in a #PBPK model for IVIVE-based prediction of fetal drug exposure.
February 3, 2025 at 11:42 AM
Publication alert 🚨: pubmed.ncbi.nlm.nih.gov/39884812/
#QconCAT-based targeted #proteomics to quantify the abundance of 6 transporters and 1 plasma protein marker in 5 placenta samples and associated cell lines and use of the data in a #PBPK model for IVIVE-based prediction of fetal drug exposure.
#QconCAT-based targeted #proteomics to quantify the abundance of 6 transporters and 1 plasma protein marker in 5 placenta samples and associated cell lines and use of the data in a #PBPK model for IVIVE-based prediction of fetal drug exposure.
#SLP Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
https://www.stocktitan.net/news/SLP/simulations-plus-announces-collaboration-with-lonza-and-u-s-fda-to-zx9p2x9b26c6.html
https://www.stocktitan.net/news/SLP/simulations-plus-announces-collaboration-with-lonza-and-u-s-fda-to-zx9p2x9b26c6.html
Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
Simulations Plus (Nasdaq: SLP) announced a funded research collaboration with Lonza and the U.S. FDA to develop and validate a mechanistic predictive framework for amorphous solid dispersion (ASD) oral products.The program pairs Lonza's advanced in vitro dissolution testing with Simulations Plus' DDDPlus and GastroPlus platforms to build IVIVE and virtual bioequivalence methods, aiming to improve prediction of food and elevated gastric pH effects and potentially reduce reliance on certain clinical bioequivalence studies while aligning with regulatory MIDD priorities.
www.stocktitan.net
April 21, 2026 at 11:55 AM
#SLP Simulations Plus Announces Collaboration with Lonza and U.S. FDA to Advance Predictive Frameworks for Complex Oral Drug Products
https://www.stocktitan.net/news/SLP/simulations-plus-announces-collaboration-with-lonza-and-u-s-fda-to-zx9p2x9b26c6.html
https://www.stocktitan.net/news/SLP/simulations-plus-announces-collaboration-with-lonza-and-u-s-fda-to-zx9p2x9b26c6.html
Mouthwashing spoilers!
Bgeb whrtb qbaqr ry cebgntbavfgn znfphyvab un pbaqranqb n onfgnagr crñn cbedhr ab fnora ivive fva qrwne yn cbyyn dhvrgn! Ab, ra frevb, gerzraqn uvfgbevn, l yb gevfgr rf dhr rf zhl pvregn, shpx wvz, dhr fr wbqna ybf pnoebarf uqc, whrtb rfghcraqífvzb
Bgeb whrtb qbaqr ry cebgntbavfgn znfphyvab un pbaqranqb n onfgnagr crñn cbedhr ab fnora ivive fva qrwne yn cbyyn dhvrgn! Ab, ra frevb, gerzraqn uvfgbevn, l yb gevfgr rf dhr rf zhl pvregn, shpx wvz, dhr fr wbqna ybf pnoebarf uqc, whrtb rfghcraqífvzb
September 11, 2025 at 6:02 PM
Mouthwashing spoilers!
Bgeb whrtb qbaqr ry cebgntbavfgn znfphyvab un pbaqranqb n onfgnagr crñn cbedhr ab fnora ivive fva qrwne yn cbyyn dhvrgn! Ab, ra frevb, gerzraqn uvfgbevn, l yb gevfgr rf dhr rf zhl pvregn, shpx wvz, dhr fr wbqna ybf pnoebarf uqc, whrtb rfghcraqífvzb
Bgeb whrtb qbaqr ry cebgntbavfgn znfphyvab un pbaqranqb n onfgnagr crñn cbedhr ab fnora ivive fva qrwne yn cbyyn dhvrgn! Ab, ra frevb, gerzraqn uvfgbevn, l yb gevfgr rf dhr rf zhl pvregn, shpx wvz, dhr fr wbqna ybf pnoebarf uqc, whrtb rfghcraqífvzb